Development and structural determination of an anti-PrPC aptamer that blocks pathological conformational conversion of prion protein

Sci Rep. 2020 Mar 18;10(1):4934. doi: 10.1038/s41598-020-61966-4.

Abstract

Prion diseases comprise a fatal neuropathy caused by the conversion of prion protein from a cellular (PrPC) to a pathological (PrPSc) isoform. Previously, we obtained an RNA aptamer, r(GGAGGAGGAGGA) (R12), that folds into a unique G-quadruplex. The R12 homodimer binds to a PrPC molecule, inhibiting PrPC-to-PrPSc conversion. Here, we developed a new RNA aptamer, r(GGAGGAGGAGGAGGAGGAGGAGGA) (R24), where two R12s are tandemly connected. The 50% inhibitory concentration for the formation of PrPSc (IC50) of R24 in scrapie-infected cell lines was ca. 100 nM, i.e., much lower than that of R12 by two orders. Except for some antibodies, R24 exhibited the lowest recorded IC50 and the highest anti-prion activity. We also developed a related aptamer, r(GGAGGAGGAGGA-A-GGAGGAGGAGGA) (R12-A-R12), IC50 being ca. 500 nM. The structure of a single R12-A-R12 molecule determined by NMR resembled that of the R12 homodimer. The quadruplex structure of either R24 or R12-A-R12 is unimolecular, and therefore the structure could be stably formed when they are administered to a prion-infected cell culture. This may be the reason they can exert high anti-prion activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aptamers, Nucleotide / chemistry*
  • Aptamers, Nucleotide / genetics
  • Aptamers, Nucleotide / pharmacology
  • Dose-Response Relationship, Drug
  • Magnetic Resonance Spectroscopy
  • Models, Molecular
  • Molecular Conformation
  • PrPSc Proteins / antagonists & inhibitors
  • PrPSc Proteins / chemistry*
  • PrPSc Proteins / genetics
  • Prion Proteins
  • SELEX Aptamer Technique*
  • Structure-Activity Relationship

Substances

  • Aptamers, Nucleotide
  • PrPSc Proteins
  • Prion Proteins